Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
How dying tumor cells get noticed: Besides killing tumor cells directly, some chemotherapies, such as anthracyclines, also activate the immune system to kill tumors. Vacchelli et al. discovered that in mice, anthracycline-induced antitumor immunity requires immune cells to express the protein formyl peptide receptor 1 (FPR1). Dendritic cells (DCs) near tumors expressed especially high amounts of FPR1. DCs normally capture fragments of dying tumor cells and use them to activate nearby T cells to kill tumors, but DCs lacking FPR1 failed to do this effectively. Individuals with breast or colon cancer expressing a variant of FPR1 and treated with anthracyclines showed poor metastasis-free and overall survival. Thus, FPR1 may affect anti-tumor immunity in people, too. Science , this issue p. 972
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This confirmed that Fpr1 deficient immune cells interacted much less with dying cancer cells treated with anthracyclines than immune cells expressing functional Fpr1 (Fig. 3B), explaining why Fpr1 deficiency leads to defective anticancer immune response and less efficient chemotherapy.”
From Microfluidics: A New Tool for Modeling Cancer–Immune Interactions (2016) · cites this paper as [62]
In the citing paper
“Recently, Vacchelli et al. identified a loss of-function mutation in the allele of the gene coding for formyl peptide receptor 1 (Fpr1) that correlated with poor survival in breast and colorectal cancer patients receiving adjuvant chemotherapy[62].”
From Microfluidics: A New Tool for Modeling Cancer–Immune Interactions (2016) · cites this paper as [62]
In the citing paper
“Extracellular ANXA1 reportedly acts as a DAMP and supports the activation of adaptive immune responses by engaging formyl peptide receptor 1 (FPR1) on DCs [876].”
From Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. (2018) · cites this paper as [876]
In the citing paper
“In line with these observations, RCD is not perceived as immunogenic when cancer cells are depleted of HMGB1 or ANXA1, as well as when the host lacks TLR4 or FPR1 [870, 876].”
From Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. (2018) · cites this paper as [876]
Citations
Cites
Fiji: an open-source platform for biological-image analysis
Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., et al. (2012) · Nature Methods · doi:10.1038/nmeth.2019 · Cited by 66,890
NIH Image to ImageJ: 25 years of image analysis
Schneider, C. A., Rasband, W. S., & Eliceiri, K. W. (2012) · Nature Methods · doi:10.1038/nmeth.2089 · Cited by 64,638
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Maere, S., Heymans, K., & Kuiper, M. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bti551 · Cited by 4,155
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Self-citationApetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
Self-citationMore powerful procedures for multiple significance testing
Hochberg, Y., & Benjamini, Y. (1990) · Statistics in Medicine · doi:10.1002/sim.4780090710 · Cited by 2,715
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898
Self-citationDenkert, C., Loibl, S., Noske, A., Roller, M., Müller, B. M., Komor, M., Budczies, J., Darb-Esfahani, S., Kronenwett, R., Hanusch, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.7370 · Cited by 1,762
Cited by
Items 201–300 of 452
The hypothesis that Helicobacter pylori predisposes to Alzheimer’s disease is biologically plausible
Contaldi, F., Capuano, F., Fulgione, A., Cigliano, R. A., Sanseverino, W., Iannelli, D., Medaglia, C., & Capparelli, R. (2017) · Scientific Reports · doi:10.1038/s41598-017-07532-x · Cited by 39
Stoll, G., Pol, J. G., Soumelis, V., Zitvogel, L., & Kroemer, G. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1484980 · Cited by 42
Self-citationAnnexin A1: A double-edged sword as novel cancer biomarker
Fu, Z., Zhang, S., Wang, B., Huang, W., Zheng, L., & Cheng, A. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.01.022 · Cited by 38
Immunogenic cell death (ICD) enhancers—Drugs that enhance the perception of ICD by dendritic cells
Liu, P., Zhao, L., Zitvogel, L., Kepp, O., & Kroemer, G. (2023) · Immunological Reviews · doi:10.1111/imr.13269 · Cited by 45
“33 Driven by the consideration that the FPR1 defects causes a clinically impactful cancer-relevant immune defect, we decided present OVA to B3Z cells, and this defect was the most profound one, in quantitative terms, among all pattern recognition receptors that we knocked out.”
BackgroundInfluentialSelf-citationCrizotinib – a tyrosine kinase inhibitor that stimulates immunogenic cell death
Liu, P., Zhao, L., Kepp, O., & Kroemer, G. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1596652 · Cited by 37
Self-citationMechanisms of immunogenic cell death and immune checkpoint blockade therapy
Lin, R. A., Lin, J. K., & Lin, S. (2021) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.12375 · Cited by 40
Yang, P., Hsieh, Y., Du, J.-L., Yen, S.-C., & Hung, C. (2020) · Biomolecules · doi:10.3390/biom10040643 · Cited by 38
“These DAMPs may function as “eat me” and “find me” signals for professional phagocytes through interacting with different phagocytic or scavenger receptors including low density lipoprotein receptor-related protein 1 (LRP1)/cluster of differentiation 91 (CD91) for CRT, purinergic receptors for ATP, pattern-recognition…”
BackgroundInfluentialImmunogenic cell stress and death in the treatment of cancer
Pan, H., Liu, P., Zhao, L., Pan, Y., Mao, M., Kroemer, G., & Kepp, O. (2023) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2023.10.007 · Cited by 39
Self-citationOdobasic, D., Yuan, J., Kao, W., Fan, H., Wei, X., Gu, R., Ngo, D., Kitching, A. R., Holdsworth, S. R., Morand, E. F., et al. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.05.028 · Cited by 33
Targeting formyl peptide receptors to facilitate the resolution of inflammation
Filep, J. G., Sekheri, M., & Kebir, D. E. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.06.025 · Cited by 36
Systemic autophagy in the therapeutic response to anthracycline-based chemotherapy
Castoldi, F., Vacchelli, E., Zitvogel, L., Maiuri, M. C., Pietrocola, F., & Kroemer, G. (2019) · OncoImmunology · doi:10.1080/2162402x.2018.1498285 · Cited by 33
Self-citationD’Orazio, M., Murdocca, M., Mencattini, A., Casti, P., Filippi, J., Antonelli, G., Giuseppe, D. D., Comes, M. C., Natale, C. D., Sangiuolo, F. C., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-12364-5 · Cited by 33
Ghiringhelli, F., & Rébé, C. (2023) · Immunological Reviews · doi:10.1111/imr.13263 · Cited by 40
“19 Second, “eat me” signal is delivered by membrane exposure of Calreticulin which facilitates the uptake of dying cancer cells by DCs, presumably through an interaction with LDL receptor related protein 1 (LRP1, best known as CD91).”
BackgroundHuang, K. C., Chiang, S., Yang, P.-C., Ke, T., Chen, T.-W., Hu, C.-H., Huang, Y., Chang, H.-Y., Chen, W. T., & Chao, K. S. C. (2021) · Cancers · doi:10.3390/cancers13061218 · Cited by 33
Tian, T., Yu, M., Li, J., Jiang, M.-Q., Ma, D., Tang, S., Lin, Z., Chen, L., Gong, Y., Zhu, J., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.739090 · Cited by 34
Therapy-induced microenvironmental changes in cancer
Ma, Y., Yang, H., Pitt, J. M., Kroemer, G., & Zitvogel, L. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1401-8 · Cited by 35
Self-citationExploiting tumor-associated dendritic cell heterogeneity for novel cancer therapies
Keirsse, J., Damme, H. V., Ginderachter, J. A. V., & Laoui, D. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.4mr1116-466r · Cited by 35
Annunziata, M. C., Parisi, M., Esposito, G., Fabbrocini, G., Ammendola, R., & Cattaneo, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113818 · Cited by 32
“On the other hand, FPR1 exerts protective role in breast and colorectal cancer, where its functional expression seems required to achieve effective therapy [36,37].”
BackgroundEriau, E., Paillet, J., Kroemer, G., & Pol, J. G. (2021) · Cancers · doi:10.3390/cancers13061260 · Cited by 33
Self-citationChen, R., Chen, C., Han, N., Guo, W., Deng, H., Wang, Y., Ding, Y., & Zhang, M. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17458 · Cited by 45
Endoplasmic reticulum stress in the cellular release of damage-associated molecular patterns
Chuang, A. W., Kepp, O., Kroemer, G., & Bezu, L. (2019) · International review of cytology · doi:10.1016/bs.ircmb.2019.11.006 · Cited by 34
Self-citationIsobacachalcone induces autophagy and improves the outcome of immunogenic chemotherapy
Wu, Q., Tian, A.-L., Durand, S., Aprahamian, F., Nirmalathasan, N., Xie, W., Liu, P., Zhao, L., Zhang, S., Pan, H., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03226-x · Cited by 31
Self-citationBiosafety of mesoporous silica nanoparticles: a combined experimental and literature study
Sun, L., Sogo, Y., Wang, X., & Ito, A. (2021) · Journal of Materials Science Materials in Medicine · doi:10.1007/s10856-021-06582-y · Cited by 35
Kim, R., & Kin, T. (2021) · Cancers · doi:10.3390/cancers13194756 · Cited by 34
Shang, Y., Lu, H., Liao, L., Li, S., Xiong, H., & Yao, J. (2023) · ACS Nano · doi:10.1021/acsnano.3c02657 · Cited by 32
Truxová, I., Hensler, M., Škapa, P., Halaška, M. J., Laco, J., Ryška, A., Spisek, R., & Fucikova, J. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.09.003 · Cited by 32
FLT3LG - a biomarker reflecting clinical responses to the immunogenic cell death inducer oxaliplatin
Pol, J. G., Naour, J. L., & Kroemer, G. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1755214 · Cited by 38
Self-citationReste, M., Ajazi, K., Sayi‐Yazgan, A., Janković, R., Bufan, B., Brandau, S., Bækkevold, E. S., Petitprez, F., Lindstedt, M., Adema, G. J., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1439413 · Cited by 35
“This mutation resulted in anthracyclines-based chemotherapy failure due to impaired recognition of dying tumor cells by DCs (75).”
Wang, J., Chen, H., Dai, S.-Z., Huang, F., Lin, Y., Wang, C.-C., Li, L., Zheng, W.-P., & Tan, G. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003950 · Cited by 29
Nanohydroxyapatite Stimulates PD-L1 Expression to Boost Melanoma Combination Immunotherapy
Yang, Y., Cui, Y., Cao, W., Zhao, M., Lin, W., Xu, R., Yang, X., Chen, Y., Li, H., Liang, J., et al. (2022) · ACS Nano · doi:10.1021/acsnano.2c07818 · Cited by 29
Dual Synergistic Tumor‐Specific Polymeric Nanoparticles for Efficient Chemo‐Immunotherapy
Xiang, J., Liu, K., Xu, H., Zhao, Z., Piao, Y., Shao, S., Tang, J., Shen, Y., & Zhou, Z. (2023) · Advanced Science · doi:10.1002/advs.202301216 · Cited by 31
Immunotherapeutic properties of chemotherapy
Fournier, C., Vargas, T. R., Martin, T. W., Melis, A., & Apétoh, L. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.05.003 · Cited by 30
Liu, L., Chen, Q., Ruan, C., Chen, X., Zhang, Y., He, X., Zhang, Y., Lü, Y., Guo, Q., Sun, T., et al. (2018) · Theranostics · doi:10.7150/thno.24110 · Cited by 27
Immunotherapy for Head and Neck Cancer
Sim, F. W., Leidner, R. S., & Bell, R. B. (2019) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.12.006 · Cited by 31
Comes, M. C., Filippi, J., Mencattini, A., Casti, P., Cerrato, G., Sauvat, A., Vacchelli, E., Ninno, A. D., Giuseppe, D. D., D’Orazio, M., et al. (2020) · Neural Computing and Applications · doi:10.1007/s00521-020-05226-6 · Cited by 28
Self-citationDuan, S., Wang, P., Liu, F., Huang, H., An, W., Pan, S., & Wang, X. (2019) · Cancer Medicine · doi:10.1002/cam4.2077 · Cited by 30
D’Orazio, M., Corsi, F., Mencattini, A., Giuseppe, D. D., Comes, M. C., Casti, P., Filippi, J., Natale, C. D., Ghibelli, L., & Martinelli, E. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.580698 · Cited by 28
“, immune– cancer cross-talk (13, 14), speed and directional persistence are needed to model their collective motion; on the other hand, in a group of cells interacting with a target cell, e.”
BackgroundBaracco, E. E., Pietrocola, F., Buqué, A., Bloy, N., Senovilla, L., Zitvogel, L., Vacchelli, E., & Kroemer, G. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1139275 · Cited by 27
“a gradient in the functional consequences of FPR1 loss-of-function alleles on the interaction between dendritic cell precursors and dying cancer cells, as detectable in a microfluidic device.(19)”
BackgroundInfluentialSelf-citationFPR1 mediates the tumorigenicity of human cervical cancer cells
Cao, G., & Zhang, Z. (2018) · Cancer Management and Research · doi:10.2147/cmar.s182795 · Cited by 25
Current Limitations and Perspectives of Chimeric Antigen Receptor-T-Cells in Acute Myeloid Leukemia
Maucher, M., Srour, M., Danhof, S., Einsele, H., Hudecek, M., & Yakoub‐Agha, I. (2021) · Cancers · doi:10.3390/cancers13246157 · Cited by 25
van Vliet, A. R., Garg, A. D., & Agostinis, P. (2016) · Biological Chemistry · doi:10.1515/hsz-2016-0108 · Cited by 27
Efferocytosis in dendritic cells: an overlooked immunoregulatory process
Ma, Y., Jiang, T., Zhu, X., Xu, Y., Wan, K., Zhang, T., & Xie, M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1415573 · Cited by 24
“Breast cancer patients with dysfunctional TLR4 alleles experience faster recurrence after radiation and chemotherapy compared to those with normal TLR4 alleles (236, 239, 240), indicating a close association between TLR4 and anti-tumor immune responses.”
BackgroundSelf-citationImmunogenic Cell Death Driven by Radiation—Impact on the Tumor Microenvironment
Yamazaki, T., Vanpouille‐Box, C., Demaria, S., & Galluzzi, L. (2020) · Cancer treatment and research · doi:10.1007/978-3-030-38862-1_10 · Cited by 28
Dendritic Cell-Based Immunotherapy in Hot and Cold Tumors
Kang, B. H., & Lee, H. K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137325 · Cited by 28
Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma
Gullà, A., Morelli, E., Johnstone, M. E., Turi, M., Samur, M., Botta, C., Cifrić, S., Folino, P., Vinaixa, D., Barello, F., et al. (2024) · Blood · doi:10.1182/blood.2023022777 · Cited by 26
More than just innate affairs – on the role of annexins in adaptive immunity
Weyd, H. (2016) · Biological Chemistry · doi:10.1515/hsz-2016-0191 · Cited by 25
“Interestingly, a recent report describes a polymorphism in the human FPR1-locus to be associated with reduced co-localization of DC and dead tumor cells and a diminished antitumor immune response (Vacchelli et al., 2015).”
BackgroundNuts and Bolts: Microfluidics for the Production of Biomaterials
Fontana, F., Martins, J. P., Torrieri, G., & Santos, H. A. (2019) · Advanced Materials Technologies · doi:10.1002/admt.201800611 · Cited by 27
Autophagy activation by dietary piceatannol enhances the efficacy of immunogenic chemotherapy
Wang, S., Wang, G., Wu, W., Xu, Z., Yang, J., Cao, M., Wang, Q., Wang, J., Yang, C., & Zhang, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.968686 · Cited by 28
Zheng, L., Wang, H., Zhong, X., Lin, J. H., Shi, G., Bai, C., Yang, R., Huang, Z., Jiang, Y., Wei, J., et al. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122809 · Cited by 24
Liu, Q., Wu, Y., Fan, Q., Liu, J., Chen, Y., He, Y., Wei, W., Zhang, H., Zhao, Y., He, Y., et al. (2025) · ACS Nano · doi:10.1021/acsnano.5c01158 · Cited by 24
A fluorescent biosensor-based platform for the discovery of immunogenic cancer cell death inducers
Kepp, O., Sauvat, A., Leduc, M., Forveille, S., Liu, P., Zhao, L., Bezu, L., Xie, W., Zitvogel, L., & Kroemer, G. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1606665 · Cited by 23
Self-citationChemotherapy and immunotherapy: A close interplay to fight cancer?
Hanoteau, A., & Moser, M. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1190061 · Cited by 23
Dynamical Boolean Modeling of Immunogenic Cell Death
Checcoli, A., Pol, J. G., Naldi, A., Noel, V., Barillot, E., Kroemer, G., Thieffry, D., Calzone, L., & Stoll, G. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.590479 · Cited by 23
Self-citationBretti, G., Ninno, A. D., Natalini, R., Peri, D., & Roselli, N. (2021) · Axioms · doi:10.3390/axioms10040243 · Cited by 24
Immunogenic cell death-inducing metal complexes: From the benchtop to the clinic
Sen, S., Karoscik, K., Maier, E. Y., & Arambula, J. F. (2023) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2023.102277 · Cited by 23
“Cyclophosphamide and analogues; a matter of dose and schedule for dual anticancer activities”
Delahousse, J., Molina, L., & Paci, A. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217119 · Cited by 29
Park, I. A., Heo, S., Song, I. H., Kim, Y., Park, H. S., Bang, W. S., Park, S. Y., Jo, J.-H., Lee, H. J., & Gong, G. (2016) · Oncotarget · doi:10.18632/oncotarget.11010 · Cited by 21
Alev, M., Egenberger, L., Mühleisen, L., Weigel, B., Frey, B., Friedrich, R. P., Pöttler, M., Alexiou, C., & Janko, C. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.07.007 · Cited by 25
The interplay between neutrophils and microbiota in cancer
Smith, C. K., & Trinchieri, G. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.4ri0418-151r · Cited by 21
Comes, M. C., Filippi, J., Mencattini, A., Corsi, F., Casti, P., Ninno, A. D., Giuseppe, D. D., D’Orazio, M., Ghibelli, L., Mattei, F., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-72605-3 · Cited by 19
Self-citationCytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross‐priming
Luri‐Rey, C., Gomis, G., Glez‐Vaz, J., Manzanal, A., Riaño, A. M., Rodriguez-Ruiz, M. E., Teijeira, Á., & Melero, I. (2023) · Immunological Reviews · doi:10.1111/imr.13281 · Cited by 24
Donlon, N. E., Sheppard, A., Davern, M., O’Connell, F., Phelan, J. J., Power, R. F., Nugent, T., Dinneen, K., Aird, J. J., Greene, J. P., et al. (2020) · Cancers · doi:10.3390/cancers12113356 · Cited by 19
Dying to survive: harnessing inflammatory cell death for better immunotherapy
Cheng, L., Wang, Y., & Zhang, Y. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.01.012 · Cited by 19
The Cancer-Immune Set Point in Oesophageal Cancer
Power, R. F., Lowery, M. A., Reynolds, J. V., & Dunne, M. R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00891 · Cited by 19
“Other cytotoxic agents (anthracyclines, cyclophosphamide, oxaliplatin, and taxanes) induce immunogenic cell death, increasing tumour adjuvanticity (164).”
BackgroundGenovese, I., Vezzani, B., Danese, A., Modesti, L., Vitto, V. A. M., Corazzi, V., Pelucchi, S., Pinton, P., & Giorgi, C. (2020) · Cell Calcium · doi:10.1016/j.ceca.2020.102308 · Cited by 22
Vacchelli, E., Ma, Y., Baracco, E. E., Zitvogel, L., & Kroemer, G. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1118600 · Cited by 20
Self-citationFasting improves anticancer immunosurveillance via autophagy induction in malignant cells
Pietrocola, F., Pol, J. G., & Kroemer, G. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1224797 · Cited by 19
“Indeed, in preclinical models, depletion of cytotoxic T lymphocytes (CTL) is sufficient to completely abolish tumor growth reduction induced by anthracyclines, cyclophosphamide or oxaliplatin.(3,4) These chemotherapeutics trigger immunogenic cell death (ICD).”
BackgroundSelf-citationPhoton- and Proton-Mediated Biological Effects: What Has Been Learned?
Jumaniyazova, E. D., Смык, Д., Vishnyakova, P., Fatkhudinov, T., & Gordon, K. B. (2022) · Life · doi:10.3390/life13010030 · Cited by 19
Microbes mediated immunogenic cell death in cancer immunotherapy
Huang, J., Duan, F., Xie, C., Xu, J., Zhang, Y., Wang, Y., Tang, Y., & Leung, E. L. (2023) · Immunological Reviews · doi:10.1111/imr.13261 · Cited by 20
“74 In summary, “eat-me” signals play an important role in both clearance of dying cells and the activation of immune system in the course of ICD.”
BackgroundImmunogenic chemotherapy: great potential for improving response rates
Huang, X., Ren, Q., Yang, L., Cui, D., Ma, C., Zheng, Y., & Wu, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1308681 · Cited by 22
“…(DAMP), including translocation of calreticulin, an endoplasmic reticulum chaperone protein, to the tumor cell surface (21), and release of lysosomal ATP (22), nuclear chromatin binding protein HMGB1 (23, 24), cytosolic protein annexin A1 (25), and/or various nucleic acids (16, 17, 24, 26, 27).”
BackgroundThe progressive trend of modeling and drug screening systems of breast cancer bone metastasis
Azar, H. K., Gharibshahian, M., Rostami, M., Mansouri, V., Sabouri, L., Beheshtizadeh, N., & Rezaei, N. (2024) · Journal of Biological Engineering · doi:10.1186/s13036-024-00408-5 · Cited by 23
“Interestingly, immune cells stimulate and inhibit the proliferation, migration, and metastasis of cancer cells [68, 69].”
BackgroundQuinacrine-mediated detection of intracellular ATP
Forveille, S., Humeau, J., Sauvat, A., Bezu, L., Kroemer, G., & Kepp, O. (2019) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2019.05.050 · Cited by 19
Self-citationDubyak, G. (2019) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2019.10.006 · Cited by 20
Chemoimmunotherapy for the treatment of prostate cancer: Insights from mathematical modelling
Valle, P. A., Coria, L. N., & Carballo, K. D. (2020) · Applied Mathematical Modelling · doi:10.1016/j.apm.2020.09.021 · Cited by 18
Impact of the ileal microbiota on colon cancer
Roberti, M. P., Rauber, C., Kroemer, G., & Zitvogel, L. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.09.016 · Cited by 18
Self-citationEditorial: Immunogenic Cell Death in Cancer: From Benchside Research to Bedside Reality
Garg, A. D., & Agostinis, P. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00110 · Cited by 20
Nanocarrier-Mediated Immunogenic Cell Death for Melanoma Treatment
Wang, J., Ma, J., Tai, Z., Li, L., Zhang, T., Cheng, T., Yu, J., Zhu, Q., Bao, L., & Chen, Z. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s434582 · Cited by 18
“38 ANAX1 secretion also affects the extracellular exposure process of CRT, leading to improved infiltration of myeloid-derived DC and CTL at tumor sites.”
BackgroundIn Situ Vaccination by Tumor Ablation: Principles and Prospects for Systemic Antitumor Immunity
Chikovani, T., & Magen, E. (2025) · Vaccines · doi:10.3390/vaccines13111114 · Cited by 18
“However, the efficacy of this approach can be modulated by tumor-intrinsic factors, such as the suppression of key innate immune sensing pathways, which may predict resistance and require additional combinatorial strategies [28–30].”
A Chemically Defined TLR3 Agonist with Anticancer Activity
Naour, J. L., Thierry, S., Scuderi, S. A., Boucard-Jourdin, M., Liu, P., Bonnin, M., Pan, Y., Perret, C., Zhao, L., Mao, M., et al. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2227510 · Cited by 18
“Fpr1 −/− mice Formyl peptide receptor 1 (FPR1) is necessary for DC homing on cancer cells that release the FPR1 ligand annexin A1 (ANXA1), which allows further cellular engagement and cross-presentation of tumor-associated antigens 8,34 .”
BackgroundSelf-citationThe role of ANXA1 in the tumor microenvironment
Li, L., Wang, B., Zhao, S., Xiong, Q., & Cheng, A. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111854 · Cited by 19
STING-cytosolic DNA sensing: the backbone for an effective tumor radiation therapy.
Liang, Y., & Peng, H. (2016) · PubMed · doi:10.3978/j.issn.2305-5839.2015.12.48 · Cited by 17
Chiang, S., Huang, K. C., Chen, W. T., Chen, T.-W., Ke, T., & Chao, K. S. C. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02894-8 · Cited by 17
Ninno, A. D., Bertani, F. R., Gerardino, A., Schiavoni, G., Musella, M., Galassi, C., Mattei, F., Sistigu, A., & Businaro, L. (2021) · Journal of Visualized Experiments · doi:10.3791/61895 · Cited by 19
Self-citationCancer predisposition syndromes: lessons for truly precision medicine
Glaire, M. A., Brown, M., Church, D. N., & Tomlinson, I. P. M. (2016) · The Journal of Pathology · doi:10.1002/path.4842 · Cited by 21
Liu, X., Song, J., Yuan, M., Zuo, F., Li, H., Tang, L., Wang, X., Wang, X., Xiao, Q., Li, L., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02265-0 · Cited by 21
“44 Thus, the roles of ANXA1-FPR1/3 should be contextualized within the broader landscape of tumor-stroma interactions.”
Zhang, L., Guan, M., Zhang, X., Yu, F., & Lai, F. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05151-w · Cited by 16
“…regulated by these signaling pathways, including metabolism, pyropto-sis, antitumor immunity, and immune checkpoint expression (Zhang et al. 2020; Vacchelli et al. 2015; Baracco et al. 2019; Pio et al. 2019; Kwak et al. 2018; Shin et al. 2020; Ives et al. 2021; Gasparrini and Audrito 2022;…”
BackgroundMethods for measuring HMGB1 release during immunogenic cell death
Zhao, L., Liu, P., Kepp, O., & Kroemer, G. (2019) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2019.05.001 · Cited by 18
Self-citationQin, J., Kunda, N. M., Qiao, G., Tulla, K. A., Prabhakar, B. S., & Maker, A. V. (2018) · Journal of Surgical Research · doi:10.1016/j.jss.2018.07.068 · Cited by 16
Immunogenic Cell Death Inducers in Cancer Immunotherapy to Turn Cold Tumors into Hot Tumors
Lucarini, V., Melaiu, O., Gragera, P., Król, K., Scaldaferri, V., Damiani, V., Ninno, A. D., Nardozi, D., Businaro, L., Masuelli, L., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26041613 · Cited by 14
“ANXA1 facilitates dendritic cell (DC) interactions with tumor debris by binding to formyl peptide receptor 1 (FPR1) [17], while HMGB1 drives DC maturation by interacting with TLR4.”
Self-citationMolecular analysis of Annexin expression in cancer
Hein, T., Krammer, P. H., & Weyd, H. (2022) · BMC Cancer · doi:10.1186/s12885-022-10075-8 · Cited by 15
Formyl peptide receptor-1 (FPR1) represses intestinal oncogenesis
Naour, J. L., Montégut, L., Pan, Y., Scuderi, S. A., Cordier, P., Joseph, A., Sauvat, A., Iebba, V., Paillet, J., Ferrere, G., et al. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2237354 · Cited by 15
“11,18 The FPR1 ligand involved in this interaction turned out to be ANXA1.”
BackgroundInfluentialSelf-citationAssessment of annexin A1 release during immunogenic cell death
Baracco, E. E., Petrazzuolo, A., & Kroemer, G. (2019) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2019.06.010 · Cited by 18
Self-citationTian, C., Chen, K., Gong, W., Yoshimura, T., Huang, J., & Wang, J. M. (2020) · Technology in Cancer Research & Treatment · doi:10.1177/1533033820973280 · Cited by 14
“On the other hand, FPR1 has been reported to increase chemotherapy-induced anticancer immune responses.(84) As reviewed in this article, FPRs are also exploited by tumor cells of the DT system to their advantage.”
BackgroundA roadmap for translational cancer glycoimmunology at single cell resolution
Peixoto, A., Miranda, A., Santos, L. L., & Ferreira, J. A. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02335-z · Cited by 16
Dendritic cell transfer for cancer immunotherapy
Zhao, L., Zhang, S., Kepp, O., Kroemer, G., & Liu, P. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.03.003 · Cited by 14
Self-citationGao, K., Li, X., Luo, S., & Zhao, L. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5639 · Cited by 16
“Loss of ANXA1 in cancer cells or lack of host FPRs function may lead to weakened chemotherapeutic capacity and shortened patient overall survival (66,94).”
BackgroundLadoire, S., Senovilla, L., Enot, D. P., Ghiringhelli, F., Poirier-Colame, V., Chaba, K., Erdag, G., Schaefer, J. T., Deacon, D. H., Zitvogel, L., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1160193 · Cited by 17
“Surface CALR then serves as an “eat-me” signal to facilitate the transfer of portions of the cancer cell into immature DCs, for subsequent cross-presentation of tumor antigens.(18) After plasma membrane permeabilization, dead cells release high mobility group B1 (HMGB1) from their nuclei.”
BackgroundSelf-citationGeorge, L., Mitra, A., Thimraj, T. A., Irmler, M., Vishweswaraiah, S., Lunding, L. P., Hühn, D., Madurga, A., Beckers, J., Fehrenbach, H., et al. (2017) · Respiratory Research · doi:10.1186/s12931-017-0629-3 · Cited by 14
“21) producing a loss-of-function allele in FPR1 is associated with poor metastasis-free and overall survival in breast and colorectal cancer patients receiving adjuvant chemotherapy [77].”
BackgroundMass-Preserving Approximation of a Chemotaxis Multi-Domain Transmission Model for Microfluidic Chips
Braun, E. C., Bretti, G., & Natalini, R. (2021) · Mathematics · doi:10.3390/math9060688 · Cited by 18
CD8+ T Cells in Immunotherapy, Radiotherapy, and Chemotherapy
Wang, W., Green, M. D., Liu, J. R., Lawrence, T. S., & Zou, W. (2017) · Springer eBooks · doi:10.1007/978-3-319-62431-0_3 · Cited by 21
Metadata
- Authors
- Vacchelli, E., Ma, Y., Baracco, E. E., Sistigu, A., Enot, D. P., Pietrocola, F., Yang, H., Adjemian, S., Chaba, K., Semeraro, M., Signore, M., De Ninno, A., Lucarini, V., Peschiaroli, F., Businaro, L., Gerardino, A., Manic, G., Ulas, T., Günther, P., Schultze, J. L., Kepp, O., Stoll, G., Lefebvre, C., Mulot, C., Castoldi, F., Rusakiewicz, S., Ladoire, S., Apetoh, L., Bravo-San Pedro, J. M., Lucattelli, M., Delarasse, C., Boige, V., Ducreux, M., Delaloge, S., Borg, C., André, F., Schiavoni, G., Vitale, I., Laurent-Puig, P., Mattei, F., Zitvogel, L., & Kroemer, G.
- Affiliations
- Inserm (FR)
- Instituto Nazionale Tumori Regina Elena (IT)
- Gustave Roussy Cancer Campus, Villejuif, France.
- Istituto Superiore di Sanità (IT)
- Italian National Research Council, Institute for Photonics and Nanotechnology, Rome, Italy.
- National Research Council (IT)
- University of Bonn (DE)
- Centre Georges François Leclerc (FR)
- Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.
- University of Siena (IT)
- Centre National de la Recherche Scientifique (FR)
- Université Paris-Saclay (FR)
- University of Rome Tor Vergata (IT)
- Université Paris Sorbonne Cité, UMRS 775, INSERM, Paris, France.
- Karolinska University Hospital (SE)
- Corresponding author
- Zitvogel, Laurence
- ORCID
- Vacchelli, Erika
- Ma, Yuting
- Sistigu, Antonella
- Pietrocola, Federico
- Yang, Heng
- Adjemian, Sandy
- Signore, Michele
- Businaro, Luca
- Gerardino, Annamaria
- Manic, Gwenola
- Ulas, Thomas
- Günther, Patrick
- Schultze, Joachim L.
- Kepp, Oliver
- Stoll, Gautier
- Mulot, Claire
- Castoldi, Francesca
- Rusakiewicz, Sylvie
- Ladoire, Sylvain
- Lucattelli, Monica
- Delarasse, Cécile
- Boige, Valérie
- Ducreux, Michel
- Delaloge, Suzette
- Borg, Christophe
- André, Fabrice
- Schiavoni, Giovanna
- Vitale, Ilio
- Mattei, Fabrizio
- Zitvogel, Laurence
- Kroemer, Guido
- Venue
- Science
- Published
- 2015-11-20
- Volume
- 350
- Issue
- 6263
- Pages
- 972-978
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1911271782
- Cited by
- 452
- References
- 40
- Citations by year
- 2026: 25 · 2025: 25 · 2024: 29 · 2023: 51 · 2022: 38 · 2021: 50 · 2020: 58 · 2019: 47 · 2018: 45 · 2017: 40 · 2016: 42 · 2015: 1
- FWCI
- 20.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Funders
- Agence Nationale de la Recherche (ANR-10-LABX-0015, ANR-10-INBS-0001, ANR-10-IBHU-0001)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- FPR1, anthracycline chemotherapy, antitumor immunity, annexin A1, cancer cell death, T cell immunity, breast cancer, colorectal cancer, adjuvant chemotherapy, loss-of-function alleles, microfluidics, metastasis-free survival
- MeSH terms
- Alleles, Animals, Breast Neoplasms, Dendritic Cells, Female, Humans, Immunity, Innate, Leukocytes, Neoplasms, T-Lymphocytes, Colorectal Neoplasms, Chemotherapy, Adjuvant, Annexin A1, Anthracyclines, Polymorphism, Single Nucleotide, Receptors, Formyl Peptide, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.